三维适形放疗联合阿帕替尼治疗晚期原发性肝细胞癌的疗效

摘要

Objective To investigate the effects of three-dimensional conformal radiotherapy (3D-CRT) combined with apatinib in the treatment of advanced hepatocellular carcinoma (AHCC). Methods A total of 86 patients with AHCC admitted to the Department of Oncology of Wuxi No.2 People's Hospital between March 2015 and June 2016 were selected as subjects. All of the patients were randomly divided into control group and observation group, 43 cases in each group. Patients in control group were treated with 3D-CRT, while patients in observation group were treated with apatinib on the basis of 3D-CRT. Enhanced CT was performed at three months after treatment. The clinical effects and adverse reactions of the two groups were compared. Serum levels of alpha-fetoprotein (AFP), vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and total bilirubin (TBIL) were measured before and after treatment. All patients were followed up for two years, and the survival rates at 6 months, 1 year and 2 years were recorded. Results At three months after treatment, the disease control rate in the ob-servation group was higher than in the control group (67.4% vs. 48.8%, P0.05). No cardiotoxicity was observed in both groups. The 1-year and 2-year survival rates of the observation group were 55.8% and 34.9% respectively, which were higher than those of the control group (32.6% and 13.9%, respectively) (P0.05);两组均未出现心脏毒性.观察组1年和2年生存率分别为55.8%和34.9%,均高于对照组的32.6%和13.9%,差异有统计学意义(P<0.05).结论 3D-CRT联合阿帕替尼治疗AHCC的疗效较好,可明显提高患者远期生存率,且不良反应可耐受,安全性较高,可能与抑制肿瘤新生血管生成有关.